{'52WeekChange': -0.23974794,
 'SandP52WeekChange': None,
 'address1': '45 Sidney Street',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 95,
 'askSize': 1100,
 'averageDailyVolume10Day': 624487,
 'averageVolume': 637784,
 'averageVolume10days': 624487,
 'beta': 1.073389,
 'beta3Year': None,
 'bid': 70.5,
 'bidSize': 1100,
 'bookValue': 12.608,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 75.94,
 'dayLow': 73.53,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -9.161,
 'enterpriseToRevenue': 48.29,
 'enterpriseValue': 3474436608,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 76.59029,
 'fiftyTwoWeekHigh': 101.76,
 'fiftyTwoWeekLow': 43.29,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 53562986,
 'forwardEps': -6.62,
 'forwardPE': -11.279456,
 'fromCurrency': None,
 'fullTimeEmployees': 394,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.01426,
 'heldPercentInstitutions': 0.97899,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/blueprintmedicines.com',
 'longBusinessSummary': 'Blueprint Medicines Corporation develops drugs of '
                        'small molecule kinase inhibitors that target genomic '
                        'drivers in genomically defined cancers, rare '
                        'diseases, and cancer immunotherapy. The company is '
                        'developing avapritinib for the treatment of systemic '
                        'mastocytosis (SM) and gastrointestinal stromal '
                        'tumors; BLU-263, an orally available, potent, and KIT '
                        'inhibitor for the treatment of indolent SM and other '
                        'mast cell disorders; and fisogatinib, an orally '
                        'available and potent inhibitor, which is in Phase I '
                        'clinical trials for the treatment of advanced '
                        'hepatocellular carcinoma. It is also developing '
                        'pralsetinib, an orally available and potent inhibitor '
                        'that targets RET, a receptor tyrosine kinase for the '
                        'treatment of RET-altered non-small cell lung cancer, '
                        'medullary thyroid carcinoma, and other solid tumors. '
                        'In addition, the company is developing BLU-782, an '
                        'oral and investigational activin-like kinase 2 '
                        'inhibitor, which is in Phase I clinical trials for '
                        'the treatment of fibrodysplasia ossificans '
                        'progressive. It has collaboration and license '
                        'agreements with Clementia Pharmaceuticals, Inc.; '
                        'CStone Pharmaceuticals; Genentech, Inc.; and F. '
                        'Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The '
                        'company was formerly known as Hoyle Pharmaceuticals, '
                        'Inc. and changed its name to Blueprint Medicines '
                        'Corporation in June 2011. Blueprint Medicines '
                        'Corporation was founded in 2008 and is headquartered '
                        'in Cambridge, Massachusetts.',
 'longName': 'Blueprint Medicines Corporation',
 'market': 'us_market',
 'marketCap': 4046367232,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_129802746',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -371241984,
 'nextFiscalYearEnd': 1640908800,
 'open': 75.37,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.48,
 'phone': '617 374 7580',
 'previousClose': 76.01,
 'priceHint': 2,
 'priceToBook': 5.92243,
 'priceToSalesTrailing12Months': 56.23938,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 75.94,
 'regularMarketDayLow': 73.53,
 'regularMarketOpen': 75.37,
 'regularMarketPreviousClose': 76.01,
 'regularMarketPrice': 75.37,
 'regularMarketVolume': 367318,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 54190000,
 'sharesPercentSharesOut': 0.0774,
 'sharesShort': 4196389,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 3645473,
 'shortName': 'Blueprint Medicines Corporation',
 'shortPercentOfFloat': 0.090500005,
 'shortRatio': 8.47,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'BPMC',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -7.43,
 'twoHundredDayAverage': 67.15288,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'ff898492-23d6-3cda-8698-a93cfd1e435b',
 'volume': 367318,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.blueprintmedicines.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02139'}